Shire Settles Intuniv Infringement Case Against Impax

Law360, New York (June 14, 2013, 4:41 PM EDT) -- Impax Laboratories Inc. has agreed to license Shire PLC's patents for the attention deficit hyperactivity disorder drug Intuniv, resolving Shire's infringement litigation over Impax's bid to launch a generic version of the drug, according to settlement papers filed Thursday in California federal court.

The two drugmakers lodged a joint stipulation for dismissal, in which Shire agreed to drop the infringement claims in exchange for Impax agreeing to pay licensing fees and vowing not to challenge the validity of Shire's three patents for Intuniv.

The other defendant...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.